At RheumaFinder, we are constantly seeking innovative solutions to improve the incidental detection of clinically relevant structural joint lesions, ultimately with the hope to better diagnose patients with a wide variety of diseases.
Approximately 40 attendees, including radiologists, rheumatologists, and entrepreneurs, gathered to hear the latest updates regarding RheumaFinder’s clinical, product, and business developments. We are thrilled to report that several participants took the initiative to invest, expanding our support base and securing the future of our company.
We proudly announce that we have successfully closed this investment round, achieving a 100% target! After 20 years of research in the field, our latest AI deep learning technology enables us to tackle the unmet need for accurate incidental detection clinically relevant structural joint lesions, which can be indicative of, amongst others but not limited to rheumatic diseases.
The insights and contributions from our investors will help us continue to innovate and redefine the future of incidental detection with AI. Stay tuned for more exciting updates from RheumaFinder as we work towards transforming healthcare through advanced technology.
Follow us on LinkedIn for the latest updates!